Neoadjuvant Chemotherapy for Osteosarcoma of the Extremities in Preadolescent Patients

Bacci, Gaetano; Balladelli, Alba; Palmerini, Emanuela; Alberghini, Marco; Pollastri, Paola; Galletti, Stefano; Mercuri, Mario; Picci, Piero

doi:10.1097/mph.0b013e31817e4aee

Cited by 32 publications

(9 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This was in line with findings of several others studies. 1 13 14 15 16 Bentzen et al stated that among conventional osteosarcomas, fibroblastic tumors had better prognosis compared with osteoblastic and chondroblastic subtypes. 17…”

Section: Discussionmentioning

confidence: 99%

Prognostic Significance of Clinical and Post-Neoadjuvant Chemotherapy Associated Histomorphological Parameters in Osteosarcoma: A Retrospective Study from a Tertiary Care Center

Vangala

Uppin

Rao

et al. 2021

Indian J Med Paediatr Oncol

View full text Add to dashboard Cite

Introduction Osteosarcoma is the most prevalent bone cancer in adolescents. Neoadjuvant chemotherapy (NACT) followed by resection is the current modality of treatment for osteosarcoma. Histological evaluation of extent of tumor necrosis on resection is a well-established prognostic indicator in osteosarcoma correlating with survival in most cases. Objectives The main objective of this study was to establish prognostic significance of various clinical and histological parameters post-NACT in osteosarcoma and to compare the integrated prognostic index proposed by Chui et al, with grading of response to NACT by Huvos and Rosen for osteosarcoma. Materials and Methods This is a retrospective study done over a period of four years and includes 47 cases of osteosarcoma treated with NACT. All slides were reviewed and association of various clinical and histological parameters with overall survival was assessed with chi-squared test and Cox-regression analysis. Results Statistical analysis revealed the prognostic significance of age at presentation, anatomic site, primary tumor size, metastatic status, and clinical stage. Histological parameters such as mitosis ≥10/10hpfs, ≥10% residual tumor were significantly associated with poor survival. Tumor necrosis ≥ 90% (excluding areas of hemorrhage, fibrosis and acellular osteoid) was significantly associated with increased survival. An integrated prognostic index formed by combining above parameters gives a better estimate of overall survival compared with residual disease or necrosis alone. Conclusion Integrated prognostic index improves prognostication in patients treated for osteosarcoma.

show abstract

Section: Discussionmentioning

confidence: 99%

Prognostic Significance of Clinical and Post-Neoadjuvant Chemotherapy Associated Histomorphological Parameters in Osteosarcoma: A Retrospective Study from a Tertiary Care Center

Vangala

Uppin

Rao

et al. 2021

Indian J Med Paediatr Oncol

View full text Add to dashboard Cite

show abstract

“…Central high-grade conventional osteosarcoma (COS) is the most common subtype, comprising 90% of all osteosarcoma variants [ 1 , 2 ]. Currently, the treatment of COS typically involves neoadjuvant chemotherapy and wide surgical excision, followed by adjuvant chemotherapy [ 3 , 4 , 5 ]. The predictors of a poor prognosis regarding survival are male sex, older age, large tumour volume, non-extremity tumour, proximal long bone sites, poor response to chemotherapy, no surgical treatment, and amputations [ 3 , 4 , 5 ].…”

Section: Introductionmentioning

confidence: 99%

A Systematic Review of the Heterogenous Gene Expression Patterns Associated with Multidrug Chemoresistance in Conventional Osteosarcoma

Mthethwa

Marais

Ramsuran

et al. 2023

Genes

View full text Add to dashboard Cite

Multidrug chemoresistance (MDR) remains the most significant obstacle to improving survival in osteosarcoma patients. Heterogeneous genetic alterations characterise the tumour microenvironment, and host molecular markers have been associated with MDR. This systematic review examines the genetic alterations of molecular biomarkers associated with multidrug chemotherapy resistance in genome-wide analysis of central high-grade conventional osteosarcoma (COS). We systematically searched MEDLINE, EMBASE, Web of Science, Wiley online library and Scopus. Only human studies involving genome-wide analysis were included, while candidate gene, in vitro and animal studies were excluded. The risk of bias of the studies was assessed using the Newcastle-Ottawa Quality Assessment Scale. The systematic search identified 1355 records. Following the screening, six studies were included in the qualitative analysis. There were 473 differentially expressed genes (DEGs) associated with chemotherapy response in COS. Fifty-seven of those were associated with MDR in osteosarcoma. The heterogeneous gene expressions were related to the mechanism of MDR in osteosarcoma. The mechanisms include drug-related sensitivity genes, bone remodelling and signal transduction. Complex, variable and heterogenous gene expression patterns underpin MDR in osteosarcoma. Further research is needed to identify the most relevant alterations for prognostication and to guide the development of possible therapeutic targets.

show abstract

“…Its incidence rate is approximately 10% in primary malignant tumor of bone, and the main site is at tubular bone of the distal end of the bone and proximal humerus (1,2). Osteosarcoma has the characteristics of high malignancy and early distal metastasis that is also the main cause of death (3,4), which is the cause of the poor prognosis of osteosarcoma patients and the less than 20% 5-year survival rate (5). With the development of new chemotherapy techniques, the survival rate of osteosarcoma patients has increased, and the 5-year survival rate is up to 80%, but the 5-year survival rate of osteosarcoma patients with metastasis has not improved significantly (6).…”

Section: Introductionmentioning

confidence: 99%

BMP‑2 and miR‑29c in osteosarcoma tissues on proliferation and invasion of osteosarcoma cells

Chen

Zhang

2019

Oncol Lett

View full text Add to dashboard Cite

Expression of bone morphogenetic protein (BMP)-2 and microRNA (miR)-29c in osteosarcoma tissues and effects on proliferation and invasion of osteosarcoma cells were investigated. A retrospective analysis of 75 patients with osteosarcoma who underwent surgery in Tianjin Baodi Hospital from May 2013 to June 2017 was conducted. A total of 75 osteosarcoma tissues and 51 normal paraneoplastic tissues were collected. RT-PCR was used to compare the expression difference of BMP-2 and miR-29c. miR-29c mimics (experimental group A) and BMP-2 siRNA plasmid (experimental group B) were transfected into human osteosarcoma cells MG-63, respectively. The transfected cells were divided into miRNA negative control (miR-NC) group (cells transfected with miR-negative control), siRNA negative control group (cells transfected with non-silent siRNA) and blank group (cells without any transfection). MTT assay was used to detect cell proliferation in each group at different time periods. Transwell insert was used to detect invasion of cells in vitro . The relative expression of BMP-2 in osteosarcoma tissue was significantly higher than that in paraneoplastic tissue (P<0.05). Τhe relative expression of miR-29c in osteosarcoma tissue was significantly lower than that in paraneoplastic tissue (P<0.05). The cell survival rates in experimental groups A and B were significantly lower than those in the blank, miR-NC negative control and siRNA negative control groups on day 5 (P<0.05). The number of cell transmembranes in experimental groups A and B was significantly lower than those in the blank, miR-NC negative control and siRNA negative control groups (P<0.05). BMP-2 is over-expressed in osteosarcoma tissues, and miR-29c is under-expressed in osteosarcoma tissues. Interfering with the expression of BMP-2 and overexpression of miR-29c can inhibit the proliferation and invasion of osteosarcoma cells, indicating that BMP-2 and miR-29c may be involved in the regulation of proliferation and metastasis of osteosarcoma cells and could be used as new molecular target markers for the diagnosis and treatment of osteosarcoma.

show abstract

Neoadjuvant Chemotherapy for Osteosarcoma of the Extremities in Preadolescent Patients

Cited by 32 publications

References 13 publications

Prognostic Significance of Clinical and Post-Neoadjuvant Chemotherapy Associated Histomorphological Parameters in Osteosarcoma: A Retrospective Study from a Tertiary Care Center

Prognostic Significance of Clinical and Post-Neoadjuvant Chemotherapy Associated Histomorphological Parameters in Osteosarcoma: A Retrospective Study from a Tertiary Care Center

A Systematic Review of the Heterogenous Gene Expression Patterns Associated with Multidrug Chemoresistance in Conventional Osteosarcoma

BMP‑2 and miR‑29c in osteosarcoma tissues on proliferation and invasion of osteosarcoma cells

Contact Info

Product

Resources

About